Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
July 01, 2021 08:00 ET | Achilles Therapeutics PLC
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:00 ET | Achilles Therapeutics PLC
LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 11, 2021 07:00 ET | Achilles Therapeutics PLC
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned - - Completed...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
May 06, 2021 08:00 ET | Achilles Therapeutics PLC
LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
May 05, 2021 08:30 ET | Achilles Therapeutics PLC
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
May 03, 2021 08:00 ET | Achilles Therapeutics PLC
LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:30 ET | Achilles Therapeutics PLC
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
April 06, 2021 16:01 ET | Achilles Therapeutics PLC
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Announces Pricing of Initial Public Offering
March 30, 2021 19:00 ET | Achilles Therapeutics PLC
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...